Impact of febrile neutropenia and colony stimulating factor use on chemotherapy delivery in patients with lymphoma: Results from the INC-EU prospective observational European neutropenia study.

被引:0
|
作者
Pettengell, Ruth
Bosly, Andre
Szucs, Thomas D.
Jackisch, Christian
Leonard, Robert
Paridaens, Robert
Constenla, Manuel
Schwenkglenks, Matthias
机构
关键词
D O I
10.1182/blood.V108.11.2444.2444
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
2444
引用
收藏
页码:692A / 692A
页数:1
相关论文
共 50 条
  • [41] Colony-Stimulating Factor Use and Impact on Febrile Neutropenia Among Patients with Newly Diagnosed Breast, Colorectal, or Non-Small Cell Lung Cancer Who Were Receiving Chemotherapy
    McCune, Jeannine S.
    Sullivan, Sean D.
    Blough, David K.
    Clarke, Lauren
    McDermott, Cara
    Malin, Jennifer
    Ramsey, Scott
    PHARMACOTHERAPY, 2012, 32 (01): : 7 - 19
  • [42] Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice
    K. Krzemieniecki
    P. Sevelda
    F. Erdkamp
    M. Smakal
    M. Schwenkglenks
    J. Puertas
    A. Trojan
    Z. Szabo
    K. Bendall
    J. Maenpaa
    Supportive Care in Cancer, 2014, 22 : 667 - 677
  • [43] Evaluation of neutropenia-related outcomes in Hodgkin's lymphoma patients with moderate or severe neutropenia who received ABVD chemotherapy without using granulocyte-colony stimulating factor
    Merdin, Alparslan
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Mert, Duygu
    Yildiz, Jale
    Basci, Semih
    Bakirtas, Mehmet
    Darcin, Tahir
    Sahin, Derya
    Ulu, Bahar Uncu
    Yigenoglu, Tugce Nur
    Batgi, Hikmetullah
    Tetik, Aysegul
    Iskender, Dicle
    Altuntas, Fevzi
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (04) : 929 - 932
  • [44] Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
    Pettengell, Ruth
    Johnson, Hans E.
    Lugtenburg, Pieternella J.
    Salar Silvestre, Antonio
    Duehrsen, Ulrich
    Rossi, Francesca G.
    Schwenkglenks, Matthias
    Bendall, Kate
    Szabo, Zsolt
    Jaeger, Ulrich
    SUPPORTIVE CARE IN CANCER, 2012, 20 (03) : 647 - 652
  • [45] Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
    Ruth Pettengell
    Hans E. Johnson
    Pieternella J. Lugtenburg
    Antonio Salar Silvestre
    Ulrich Dührsen
    Francesca G. Rossi
    Matthias Schwenkglenks
    Kate Bendall
    Zsolt Szabo
    Ulrich Jaeger
    Supportive Care in Cancer, 2012, 20 : 647 - 652
  • [46] Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR
    Fietz, Thomas
    Lueck, Andreas
    Schulz, Holger
    Harde, Johanna
    Losem, Christoph
    Grebhardt, Sina
    Wolff, Thomas
    Potthoff, Karin
    Mueller, Udo
    Zaiss, Matthias
    Kurbacher, Christian Martin
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (07) : 1127 - 1138
  • [47] Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
    Ahuva Averin
    Amanda Silvia
    Lois Lamerato
    Kathryn Richert-Boe
    Manpreet Kaur
    Devi Sundaresan
    Neel Shah
    Mark Hatfield
    Tatiana Lawrence
    Gary H. Lyman
    Derek Weycker
    Supportive Care in Cancer, 2021, 29 : 2179 - 2186
  • [48] Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice
    Averin, Ahuva
    Silvia, Amanda
    Lamerato, Lois
    Richert-Boe, Kathryn
    Kaur, Manpreet
    Sundaresan, Devi
    Shah, Neel
    Hatfield, Mark
    Lawrence, Tatiana
    Lyman, Gary H.
    Weycker, Derek
    SUPPORTIVE CARE IN CANCER, 2021, 29 (04) : 2179 - 2186
  • [49] Incidence of severe and febrile neutropenia in cancer patients treated with myelosuppressive chemotherapy in real clinical oncology practice: Preliminary results from the FLAME study.
    Snegovoy, Anton
    Kononenko, Inessa
    Chernova, Alexandra
    Shepel, Artem
    Kaleikina, Liliya
    Shalina, Anna
    Sharov, Sergey
    Pavlova, Elena
    Goldshmidt, Petr
    Dergunov, Alexander
    Safin, Rustem
    Pimonova, Irina
    Yukalchuk, Denis
    Soroka, Svetlana
    Mikhaluk, Viktorya
    Vladimirova, Liubov Yu
    Yavorskaya, Marina
    Starostina, Tatiyana
    Tkachenko, Svetlana
    Sorokina, Irina
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18740 - E18740
  • [50] Evaluating the appropriateness of granulocyte colony-stimulating factor (G-CSF) use in patients (pts) receiving myelosuppressive chemotherapy by febrile neutropenia (FN) risk level.
    Baig, Hassam
    Klippel, Zandra Karina
    Pirolli, Melissa A.
    Somlo, Barbara
    Eisen, Melissa
    Stryker, Scott
    Tzivelekis, Spiros
    Morrow, Phuong Khanh H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)